Table 4 Risk factors for MPP with A2063G mutation
Characteristics | Without A2063G mutation (n = 47) | With A2063G mutation (n = 60) | P value |
|---|---|---|---|
Age (y) | 3.792 ± 3.537 | 4.642 ± 3.069 | 0.187 |
Gender (male/female) | 23(58.97) | 32(53.33) | 0.699 |
Clinical presentation | |||
 Wheezing, No. (%) | 10(25.64) | 10(16.67) | 0.621 |
 Hypoxemia, No. (%) | 8(20.51) | 8(13.33) | 0.599 |
 Extrapulmonary complications, No. (%) | 9(23.08) | 10(16.67) | 0.802 |
 Duration of fever (d) | 7.234 ± 6.356 | 8.050 ± 5.293 | 0.470 |
 Duration of wheezing (d) | 0.00(0.00,6.50) | 0.00(0.00,5.00) | 0.499 |
 Fever longer than 7 days, No. (%) | 16(41.03) | 35(56.33) | 0.019 |
Imaging features, No. (%) | Â | ||
 Consolidation, No. (%) | 30(76.92) | 29(48.33) | 0.122 |
 Interstitial changes, No. (%) | 16(41.03) | 26(43.33) | 0.425 |
Laboratory tests, No. (%) | |||
 White blood cell count (*109/L) | 9.274 ± 3.179 | 8.740 ± 3.701 | 0.433 |
 Lymphocyte percentage (%) | 35.023 ± 15.922 | 34.410 ± 14.142 | 0.834 |
 C-reactive protein (mg/l) | 13.00(8.00,29.00) | 11.00(4.50,22.00) | 0.107 |
 ESR (mm/h) | 29.950 ± 21.995 | 36.620 ± 21.102 | 0.136 |
Treatment | |||
 No fever within 48 h after application of macrolides, No. (%) | 21(53.85) | 10(16.67) | 0.002 |
 Application of glucocorticoids, No. (%) | 24(61.54) | 44(73.33) | 0.026 |
 Mechanical ventilation, No. (%) | 4(10.26) | 3(5.00) | 0.697 |